Immunisation Advisory Committee

The Immunisation Advisory Committee gives Pharmac expert advice about which vaccines to fund and who should be eligible.

Latest updates

22 September 2026 Provisional recommendations from September 2026 meeting added

Members of the Immunisation Advisory Committee

Dr Helen Evans – Paediatric Gastroenterology and Hepatology (Chair, PTAC Member)
Prof Stephen Munn – Transplant Surgeon (PTAC Member)
Prof Stuart Dalziel – Paediatrician
Dr Sean Hanna – General Practitioner
Assoc Prof Lance Jennings – Clinical Virologist
Dr Osman Mansoor – Public Health Physician / Medical Officer of Health
Prof David Murdoch – Clinical Microbiologist / Infectious Diseases Specialist
Dr Edwin (Gary) Reynolds – General Practitioner
Dr Erasmus Smit – Clinical Virologist
Prof Nikki Turner – Principal Medical Advisor Immunisation Advisory Centre and General Practitioner
Prof James Ussher – Consultant Clinical Microbiologist
Dr Tony Walls – Paediatrician / Infectious Diseases Specialist

2026 Committee meetings

Agenda for Immunisation Advisory Committee meeting September 2026

More information on provisional recommendations

September 2026 Immunisation Advisory Committee meeting summary of provisional recommendations

The Immunisation Advisory Committee also discussed applications in progress for meningococcal, shingles, and RSV vaccines at this meeting. These discussions focused on developing access criteria and other questions from Pharmac. No funding recommendations were made.

Further information and updates for all applications discussed will be explained in the full meeting record.

Pharmaceutical and Indication	Provisional Recommendation
Human Papillomavirus 9-valent vaccine(external link) widening access to people who are living with HIV who are aged 9 up to 45 years (currently funded up to 26 years), within the context of vaccines and immunisation	Decline

September 2026 Immunisation Advisory Committee meeting summary of provisional recommendations [PDF, 86 KB]

Released 22 September 2026

May 2026 Immunisation Advisory Committee meeting summary of provisional recommendations

Pharmaceutical and Indication	Provisional Recommendation
Pertussis vaccine(external link) widened access for parents and primary caregivers of infants admitted to neonatal intensive care unit or specialist baby care units, within the context of vaccines and immunisation, subject to criteria	High priority
Meningococcal ACWY vaccine(external link) widened access to include one dose for children 1 to 4 years of age inclusive, within the context of vaccines and immunisation (to supersede all previous recommendations for this age group)	High priority
Meningococcal ACWY vaccine(external link) widened access to include one dose and one booster dose after 5 years, for adolescents or young adults 14 to 21 years of age inclusive, within the context of vaccines and immunisation, subject to criteria (to supersede all previous recommendations for this age group)	High priority
Meningococcal MenB(external link) and MenACWY(external link) vaccines widened access to provide a booster dose for adolescents in an eligible setting, within the context of vaccines and immunisation, subject to the eligibility criteria	High priority
Hepatitis A vaccination(external link) for the immunisation of people living with HIV, within the context of vaccines and immunisation	Declined
Hepatitis A vaccination(external link) for the immunisation of people living with HIV who are at increased risk, within the context of vaccines and immunisation	Declined
Clesrovimab(external link) for all infants at birth or in their first RSV season, and for high-risk infants entering their second RSV season, within the context of vaccines and immunisation, subject to criteria	High priority
RSVpreF vaccine(external link) (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in infants by active immunisation of pregnant individuals, within the context of vaccines and immunisation, subject to criteria	High priority
RSVpreF vaccine(external link) (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older, within the context of vaccines and immunisation, subject to criteria	Medium priority
RSVpreF vaccine(external link) (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 to 74 years with eligible comorbidities and all adults 75 years of age and older, within the context of vaccines and immunisation, subject to criteria	High priority
RSVpreF vaccine(external link) (Abrysvo) for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in people who are immunocompromised, within the context of vaccines and immunisation	Deferred*

*Deferred – the Committee has recommended that the application be deferred until there is updated/additional clinical evidence available to support this application

Summary of provisional recommendations of the May 2026 Immunisation Advisory Committee meeting [PDF, 97 KB]

Released 3 July 2026

Agenda for May 2026 Immunisation Advisory Committee (IAC) meeting